https://biopharmagovernance.com 2026-04-05T17:11:12.824Z weekly 1 https://biopharmagovernance.com/articles 2026-04-05T17:11:12.824Z weekly 0.9 https://biopharmagovernance.com/pillars 2026-04-05T17:11:12.824Z monthly 0.7 https://biopharmagovernance.com/about 2026-04-05T17:11:12.824Z monthly 0.5 https://biopharmagovernance.com/advisory 2026-04-05T17:11:12.824Z monthly 0.5 https://biopharmagovernance.com/newsletter 2026-04-05T17:11:12.824Z monthly 0.6 https://biopharmagovernance.com/pillars/governance-fundamentals 2026-04-05T17:11:12.824Z weekly 0.7 https://biopharmagovernance.com/pillars/clinical-decision-making 2026-04-05T17:11:12.824Z weekly 0.7 https://biopharmagovernance.com/pillars/capital-strategic 2026-04-05T17:11:12.824Z weekly 0.7 https://biopharmagovernance.com/pillars/board-dynamics 2026-04-05T17:11:12.824Z weekly 0.7 https://biopharmagovernance.com/articles/handling-an-underperforming-board-member 2026-04-07T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/evaluating-licensing-deals-board-perspective 2026-03-30T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/ceo-evaluation-clinical-stage-company 2026-03-26T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/managing-runway-pressure-without-panic 2026-03-15T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/how-boards-should-evaluate-ambiguous-clinical-data 2026-03-08T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/unwritten-rules-effective-biopharma-boards 2026-02-28T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/board-role-trial-go-no-go-decisions 2026-02-27T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/biopharma-board-governance-differs-from-traditional 2026-02-24T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/governance-vs-management-clinical-development 2026-02-20T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/board-composition-strategy-five-seats 2026-02-17T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/governance-during-fundraising 2026-02-13T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/fiduciary-duties-clinical-stage-context 2026-02-10T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/managing-investor-independent-director-tension 2026-02-06T00:00:00.000Z monthly 0.8 https://biopharmagovernance.com/articles/first-90-days-on-biopharma-board 2026-02-03T00:00:00.000Z monthly 0.8